Diet for Hypoglycemia

Home > Hypoglycemia Treatment Insulin Information > Hypoglycemia Treatment Insulin News

Hypoglycemia Treatment Insulin News

  • New Clinical Study Shows Patients With Type 2 Diabetes May Be Able To Tolerate Higher Doses Of Metformin Using GLUMETZA Tuesday, June 29, 2010 @ 6:48AMDepomed, Inc. (NASDAQ:DEPO) and Santarus, Inc. (NASDAQ:SNTS) announced new data suggesting that patients previously intolerant of metformin may be able to tolerate higher doses of metformin when treated with GLUMETZA® (metformin HCl extended release tablets). The findings [abstract #0729-P] will be presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando ...
  • Less Glycemic Variability, Better Patient Reported Outcomes With Lantus® And Apidra® Regimen Vs. Premix Analog Insulin Tuesday, June 29, 2010 @ 6:48AMSanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced results of a study which demonstrated that patients using Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were ...
  • First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010 Monday, June 28, 2010 @ 7:53AMAmylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual ...
  • Biodel, Arena Pharma: Volume Movers Monday, June 28, 2010 @ 7:13AMSeveral stocks trading near $5, including Biodel, were poised to move on above-average volume during Monday's session.
  • Reducing niacin intake can prevent obesity Thursday, May 20, 2010 @ 10:18AMA research team from China explored the mechanism underlying niacin's action on glucose metabolism, and the association between the US per capita niacin consumption and the obesity prevalence in the US. They found there is a close correlation between the niacin consumption and the obesity prevalence in the US population. The increased obesity prevalence in the US children in the past three ...
  • Reducing niacin intake can prevent obesity Thursday, May 20, 2010 @ 10:11AM( World Journal of Gastroenterology ) A research team from China explored the mechanism underlying niacin's action on glucose metabolism, and the association between the US per capita niacin consumption and the obesity prevalence in the US. They found there is a close correlation between the niacin consumption and the obesity prevalence in the US population. The increased obesity prevalence in ...
  • FDA Approves Diabetes Management System Monday, March 22, 2010 @ 3:58AMThe U.S. Food and Drug Administration has approved a diabetes management system that combines an insulin pump with a glucose monitoring system. This diabetes management system, manufactured by Medtronic, is called MiniMed Paradigm REAL-Time Revel System .
  • Diabetes' link to eating disorders explored Monday, March 15, 2010 @ 10:26PMDiabetics, under the gun to better manage their disease by controlling their food intake and weight, may find themselves in the sticky wicket of needing treatment that makes them hungry, researchers said.
  • Research and Markets: Disposable Medical Supplies/Durable Medical Equipment (2010 Update) Monday, February 22, 2010 @ 4:52AMDUBLIN----Research and Markets has announced the addition of the "Disposable Medical Supplies/Durable Medical Equipment " report to their offering. An important UM resource tool. Hundreds of medical necessity review criteria clinical guidelines for medical supplies and DME.
  • New diabetes drug shows promise in trial Tuesday, June 9, 2009 @ 10:20AMMONDAY, June 8 (HealthDay News) -- An experimental diabetes drug called liraglutide appears to outperform exenatide (Byetta), the only currently approved drug in its class, a study funded by liraglutide's maker, Novo Nordisk, shows.